Verve Therapeutics. has filed a patent for engineered polynucleotides that can form a guide nucleic acid with an editing template. The hybridized guide nucleic acids can be used with template-based gene editors to make edits in a target genomic location. GlobalData’s report on Verve Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Verve Therapeutics, CRISPR nucleases was a key innovation area identified from patents. Verve Therapeutics's grant share as of January 2024 was 3%. Grant share is based on the ratio of number of grants to total number of patents.
Template-based gene editing using hybridized guide nucleic acids
See Also:
A recently filed patent (Publication Number: US20240011023A1) discloses a novel hybridized guide nucleic acid for use with a template-based editor. The invention comprises a first polynucleotide with a guide nucleic acid element and a hybridization sequence, along with a second polynucleotide containing an editing template as the guide nucleic acid element. These polynucleotides have complementary hybridization sequences that are hybridized to each other, enabling precise editing in the template-based editor system. Additionally, the patent claims a method for forming the hybridized guide nucleic acid by hybridizing each polynucleotide to another, ensuring the hybridization sequences align correctly for effective editing.
Furthermore, the patent extends to a template-based gene editor system incorporating the hybridized guide nucleic acid, along with pharmaceutical compositions containing the editor system and lipid nanoparticles. The composition of the hybridized guide nucleic acid includes multiple polynucleotides, each with a gRNA element and a hybridization sequence, engineered to hybridize and form a functional guide nucleic acid for template-based editing. This innovative approach offers a promising solution for precise genetic editing, with potential applications in various fields requiring targeted modifications at the nucleic acid level.
To know more about GlobalData’s detailed insights on Verve Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
